ADMA Biologics ADMA Cumulative Cost Basis
Cumulative Cost Basis at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentGross.
The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about ADMA Biologics's cumulative cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is ADMA Biologics's cumulative cost basis?
- ADMA Biologics (ADMA) reported cumulative cost basis of $105.01M in Q1 2026.
- How has ADMA Biologics's cumulative cost basis changed year-over-year?
- ADMA Biologics's cumulative cost basis increased by 12.7% year-over-year, from $93.21M to $105.01M.
- What is the long-term trend for ADMA Biologics's cumulative cost basis?
- Over 5 years (2020 to 2025), ADMA Biologics's cumulative cost basis has grown at a 15.4% compound annual growth rate (CAGR), from $50.46M to $103.41M.